BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, August 2, 2026
Home » Topics » Financings

Financings
Financings RSS Feed RSS

Financings for Sept. 9, 2025

Sep. 9, 2025
Biopharmas in Asia-Pacific raising money in public or private financings: Microbiotix, Propanc Biopharma.
Read More
European investing illustration
LSI Europe ‘25

Key points for AI companies to attract investment in health care

Sep. 8, 2025
By Shani Alexander
Companies developing AI-based health care solutions need to ensure they have quality data, a solution that can easily integrate into clinical workflow systems and teams with evolving skills, to attract investment, delegates heard at the LSI Europe ’25 conference in London.
Read More

Financings for Sept. 8, 2025

Sep. 8, 2025
Med-tech firms raising money in public or private financings, including: Madison Scientific, MadSci.
Read More

Financings for Sept. 8, 2025

Sep. 8, 2025
Biopharmas raising money in public or private financings, including: Genix, Mineralys, Rapafusyn.
Read More
Neil Miller, CEO, NRG Therapeutics

NRG raises $67M to test mitochondrial pore inhibitor in ALS

Sep. 8, 2025
By Nuala Moran
No Comments
Neurosciences specialist NRG Therapeutics Ltd. is poised to put its new class of small-molecule regulators of the mitochondrial permeability transition pore to the test after closing an oversubscribed £50 million (US$67 million) series B.
Read More
DNA, dollars illustration

Epigenic raises $60M series B for gene therapies

Sep. 8, 2025
By Tamra Sami
No Comments
Epigenic Therapeutics Co. Ltd. closed a $60 million series B round to support clinical development of lead gene therapy candidates EPI-003 for chronic hepatitis B virus and EPI-001 for hypercholesterolemia.
Read More

Financings for Sept. 5, 2025

Sep. 5, 2025
Med-tech firms raising money in public or private financings, including: Aethlon, Joint AI, Octave, Sotera, Strata.
Read More

Financings for Sept. 5, 2025

Sep. 5, 2025
Biopharmas raising money in public or private financings, including: Artelo, Atlas, Congruence, Enveda, Mesoblast, Syantra.
Read More
Hand holding gear, dollar sign
Biopharma financings August 2025

Year's $40B in funding aligns with post-COVID normalization

Sep. 5, 2025
By Amanda Lanier
No Comments
Biopharma financing activity has continued to remain low compared to the highs seen in recent years, with a total of $39.83 billion raised across IPOs, follow-on offerings, public/other and private financings in the first eight months of 2025.
Read More
Illustration of immunoglobulin A with secretory IgA
Gastrointestinal

NIH support for Lactiga’s sIgA antibody for IBD

Sep. 5, 2025
No Comments
Lactiga US Inc. has received an award from the NIH’s National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to advance the development of its secretory IgA (sIgA) antibody for inflammatory bowel disease (IBD).
Read More
Previous 1 2 … 75 76 77 78 79 80 81 82 83 … 688 689 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 31, 2026.
  • Illustration of dopamine signaling in the brain

    New schizophrenia targets challenge trial design

    BioWorld
    The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
  • HIV virus

    AIDS 2026: New targets for metabolic dysfunction despite ART

    BioWorld
    Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 28, 2026
  • Jingxin discloses new muscarinic and sigma receptor agonists

    BioWorld Science
    Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
    • Videos
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing